newswirelogo

  • SAN JOSE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM) is clarifying the Company's full fiscal year 2021 non-GAAP diluted earnings per share guidance as disclosed in a press release issued on November 30, 2020. Full fiscal year 2021 non-GAAP diluted earnings per share is expected to be $2.89 to $2.91, instead of $2.85 to $2.87.

  • NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Berry Corporation ("Berry" or the "Company") (NASDAQ: BRY) (i) in connection with the Initial Public Offering (“IPO”) on July 26, 2018; and/or (ii) from July 26, 2018 through November 3, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of Texas alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.

  • DANBURY, Conn., Dec. 01, 2020 (GLOBE NEWSWIRE) --FuelCell Energy, Inc. (Nasdaq: FCEL) (“FuelCell Energy” or the “Company”) today announced the pricing of its underwritten public offering of 34,518,539 shares of its common stock (the “Offering”), at a public offering price of $6.50 per share. The Offering consists of 19,822,219 shares being sold by the Company and 14,696,320 shares being sold by certain selling stockholders, resulting in aggregate gross proceeds of $128.8 million to the Company and $95.5 million to the selling stockholders. The Company will not receive any proceeds from the sale of its common stock by the selling stockholders. The Offering is expected to close on or about December 3, 2020, subject to customary closing conditions. FuelCell Energy has also granted the underwriters a 30-day option to purchase up to 5,177,781 additional shares of its common stock.

  • PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. The offering is expected to close on or about December 4, 2020, subject to customary closing conditions.

  • NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions.

Corporate Head Office

Construction Today Magazine

Cringleford Business Centre
Intwood Road
Cringleford, Norwich, UK
NR4 6AU

Click here for a full list of contacts.

North American Office

Construction Today Magazine

Finelight Media
207 E. Ohio Street Suite 351
Chicago, IL 60611

Click here for a full list of contacts.

Back To Top